AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18767582 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Danazol (medication group)
Number of subjects: 66
Study 15933482 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 25 mg
Number of subjects: 0
Study 15933482 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 50 mg
Number of subjects: 0
Study 15933482 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 75 mg
Number of subjects: 0
Study 15933482 — intervention group
Group type: COMPARATOR
Intervention: Long-acting risperidone (all doses)
Number of subjects: 0
Study 15933482 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (50-week study)
Number of subjects: 0
Study 12870776 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (9 g)
Number of subjects: 11
Study 12870776 — intervention group
Group type: COMPARATOR
Intervention: Control (50 g glucose without guar)
Number of subjects: 11
Study 10554499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group (15 micrograms.kg‐1 bolus dose + 0.1 microgram.kg‐1.min‐1 infusion, n = 9)
Number of subjects: 17
Study 10554499 — intervention group
Group type: COMPARATOR
Intervention: Non-bolus group (0.1 microgram.kg‐1.min‐1 infusion, n = 8)
Number of subjects: 17
Study 8686675 — intervention group
Group type: EXPERIMENTAL
Intervention: TRD-B (tongue retaining device with anterior bulb)
Number of subjects: 16
Study 8686675 — intervention group
Group type: EXPERIMENTAL
Intervention: TRD-A (tongue retaining device without anterior bulb)
Number of subjects: 16
Study 8686675 — intervention group
Group type: EXPERIMENTAL
Intervention: TRD-A
Number of subjects: 16
Study 8686675 — intervention group
Group type: EXPERIMENTAL
Intervention: TRD-X (tongue resting outside anterior bulb)
Number of subjects: 16
Study 1878533 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS-1
Number of subjects: 0
Study 1878533 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS-2
Number of subjects: 0
Study 1878533 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6847336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 15 mg/day
Number of subjects: 12
Study 6847336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31167875 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (reference) after PCI
Number of subjects: 0
Study 31167875 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (reference) after CABG
Number of subjects: 0
Study 31167875 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT plus an anticoagulant (Triple Therapy)
Number of subjects: 0
Study 30239243 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Programme
Number of subjects: 32
Study 30239243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 26944692 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) health coaching in addition to usual care
Number of subjects: 668
Study 26944692 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 668
Study 24485480 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized psychosocial laboratory stressor (the Trier Social Stress Test for Children)
Number of subjects: 39
Study 24485480 — intervention group
Group type: COMPARATOR
Intervention: Control condition without exposure to socio‐evaluative stress
Number of subjects: 39
Study 22075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire (GW) cannulation
Number of subjects: 1249
Study 22075192 — intervention group
Group type: COMPARATOR
Intervention: Contrast injection (ConI)
Number of subjects: 1249
Study 22075192 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 1249
Study 22075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients
Number of subjects: 1249
Study 22075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintended MPD cannulation or opacification with GW
Number of subjects: 1249
Study 22075192 — intervention group
Group type: COMPARATOR
Intervention: Unintended MPD cannulation or opacification with ConI
Number of subjects: 1249
Study 22075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the MPD
Number of subjects: 1249
Study 20854343 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission Service (AS)
Number of subjects: 314
Study 20854343 — intervention group
Group type: COMPARATOR
Intervention: Standard admission process
Number of subjects: 314
Study 17932353 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted telephone support provided by a Prevention Care Manager (PCM)
Number of subjects: 1346
Study 15939927 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Number of subjects: 155
Study 15939927 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care (Control)
Number of subjects: 155
Study 12495391 — intervention group
Group type: COMPARATOR
Intervention: VVI‐40 (ventricular backup pacing at 40/min; n = 256)
Number of subjects: 506
Study 12495391 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR‐70 (dual‐chamber rate‐responsive pacing at 70/min; n = 250)
Number of subjects: 506
Study 12495391 — intervention group
Group type: COMPARATOR
Intervention: VVI‐40
Number of subjects: 506
Study 12495391 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR‐70
Number of subjects: 506
Study 9661644 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metformin, x 3 daily for 2 months
Number of subjects: 26
Study 9661644 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metformin, x 3 daily for 4-6 months (in 12 women)
Number of subjects: 26
Study 7631730 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pelvic floor stimulator
Number of subjects: 52
Study 2739017 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen during recovery period
Number of subjects: 12
Study 2739017 — intervention group
Group type: COMPARATOR
Intervention: room air during recovery period
Number of subjects: 12
Study 31438896 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar Suitcase
Number of subjects: 30
Study 28235705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge administered immediately prior to the stressor
Number of subjects: 84
Study 28235705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge administered 10 minutes prior to the stressor
Number of subjects: 84
Study 28235705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge administered prior to the stressor
Number of subjects: 84
Study 28235705 — intervention group
Group type: COMPARATOR
Intervention: Nicotine lozenge administered after the stressor
Number of subjects: 84
Study 25906190 — intervention group
Group type: EXPERIMENTAL
Intervention: PKA‐BIS protocol (combined propofol and ketamine hydrochloride anesthesia with bispectral index monitoring)
Number of subjects: 30
Study 25906190 — intervention group
Group type: EXPERIMENTAL
Intervention: PKA‐BIS protocol
Number of subjects: 30
Study 22930256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (rituximab and azathioprine)
Number of subjects: 7
Study 16547531 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 16547531 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers with vasodilatory properties
Number of subjects: 0
Study 12867587 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg methylprednisolone acetate (MPA)
Number of subjects: 77
Study 12867587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10619792 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CPB chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) and peripheral blood progenitor cell support (PBPCS)
Number of subjects: 150
Study 10619792 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CPB chemotherapy (SDC)
Number of subjects: 150
Study 10619792 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction CAF chemotherapy
Number of subjects: 150
Study 10619792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment for DPTS
Number of subjects: 150
Study 8926668 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-cross plasty with preservation of tunics and placement of their edges under the back muscles
Number of subjects: 115
Study 8926668 — intervention group
Group type: COMPARATOR
Intervention: Muscular-fascial plasty
Number of subjects: 115
Study 8926668 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-cross plasty
Number of subjects: 115
Study 1629142 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5-20 mg daily, mean dose 7.2 mg)
Number of subjects: 30
Study 6091248 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (100 micrograms i.m. daily for 15 days during 6 consecutive months)
Number of subjects: 20
Study 6091248 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo injections)
Number of subjects: 20
Study 31200638 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion (1 mg bolus over 30 min followed by 2 μg/kg/h continuous infusion)
Number of subjects: 50
Study 31200638 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 50
Study 31200638 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 50
Study 31200638 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion and Control (normal saline)
Number of subjects: 50
Study 28729617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrical stimulation (ES) of the calf muscles
Number of subjects: 13
Study 28729617 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation (ES) of the calf muscles
Number of subjects: 13
Study 25840790 — intervention group
Group type: EXPERIMENTAL
Intervention: TWG technique
Number of subjects: 80
Study 25840790 — intervention group
Group type: COMPARATOR
Intervention: CS technique
Number of subjects: 80
Study 23489466 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine (0.5%)
Number of subjects: 3
Study 23489466 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 3
Study 20808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms (IS) assessment through standardized questionnaires
Number of subjects: 5846
Study 20808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression analyses stratified by gender
Number of subjects: 5846
Study 20808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor in insomnia symptoms
Number of subjects: 5846
Study 20808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Loud snoring as a factor in insomnia symptoms
Number of subjects: 5846
Study 20808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) as a factor in insomnia symptoms
Number of subjects: 5846
Study 20808113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy, Mediterranean diet, caffeine and alcohol intake as protective factors
Number of subjects: 5846
Study 19331578 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(6)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Number of subjects: 90
Study 19331578 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(8)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Number of subjects: 90
Study 19331578 — intervention group
Group type: COMPARATOR
Intervention: Sexually active participants engaging in sexual intercourse with condoms
Number of subjects: 90
Study 19331578 — intervention group
Group type: COMPARATOR
Intervention: Sexually active participants having unprotected sex
Number of subjects: 90
Study 17342295 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Depo-Medrol
Number of subjects: 84
Study 17342295 — intervention group
Group type: COMPARATOR
Intervention: 40 mg Depo-Medrol
Number of subjects: 84
Study 14761108 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-completed ALPHA form
Number of subjects: 76
Study 14761108 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported ALPHA form
Number of subjects: 76
Study 14761108 — intervention group
Group type: COMPARATOR
Intervention: Provider type (Physicians vs. PHNs)
Number of subjects: 76
Study 11672948 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg bodyweight)
Number of subjects: 50
Study 11672948 — intervention group
Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 50
Study 9626212 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE (cisplatin, vincristine, doxorubicin, etoposide + G-CSF)
Number of subjects: 227
Study 9626212 — intervention group
Group type: COMPARATOR
Intervention: CAV/PE (cyclophosphamide, doxorubicin, vincristine, cisplatin, etoposide)
Number of subjects: 227
Study 7842516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2125 M sucrose
Number of subjects: 2
Study 7842516 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 2
Study 3339217 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week exercise program (3 hours/week)
Number of subjects: 35
Study 3339217 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study 3339217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 35
Study 31645430 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ART
Number of subjects: 76
Study 28665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy dog (TD) exposure (n = 31)
Number of subjects: 61
Study 28665340 — intervention group
Group type: COMPARATOR
Intervention: No-dog control (C) (n = 30)
Number of subjects: 61
Study 25229260 — intervention group
Group type: EXPERIMENTAL
Intervention: Early exercise regime (5‐6 times for 45 minutes during and after radiotherapy supervised by a physiotherapist)
Number of subjects: 100
Study 25229260 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 100
Study 23243082 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg elemental iron once weekly (group A)
Number of subjects: 210
Study 23243082 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg elemental iron once daily (group B)
Number of subjects: 210
Study 23243082 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml of a natural color additive (control group C)
Number of subjects: 210
Study 21676056 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 50
Study 21676056 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 50
Study 17960589 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Number of subjects: 0
Study 17960589 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-learning program
Number of subjects: 0
Study 17960589 — intervention group
Group type: COMPARATOR
Intervention: Individual or no therapy (Control)
Number of subjects: 0
Study 16495730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m EC scintigraphy
Number of subjects: 62
Study 16495730 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m DMSA scintigraphy
Number of subjects: 62
Study 16495730 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of DRF
Number of subjects: 62
Study 15598063 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based pharmaceutical care for the elderly
Number of subjects: 0
Study 15598063 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10866043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and/or subcutaneous insulin in 29 patients with newly diagnosed type 1 diabetes
Number of subjects: 53
Study 10866043 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin prophylaxis in 14 islet cell antibody-positive relatives
Number of subjects: 53
Study 10866043 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) plus subcutaneous insulin in 10 newly diagnosed patients
Number of subjects: 53
Study 9349929 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (1.2 mg salbutamol, 12 x 100 micrograms)
Number of subjects: 8
Study 9349929 — intervention group
Group type: COMPARATOR
Intervention: Diskus (1.2 mg salbutamol, 6 x 200 micrograms)
Number of subjects: 8
Study 1439642 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture closure (interrupted sutures of 000 polyester)
Number of subjects: 304
Study 1439642 — intervention group
Group type: COMPARATOR
Intervention: Stapling closure (autosuture stapler)
Number of subjects: 304
Study 1439642 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture closure
Number of subjects: 304
Study 1439642 — intervention group
Group type: COMPARATOR
Intervention: Stapling closure
Number of subjects: 304
Study 2991486 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV (procarbazine, CCNU, and vincristine)
Number of subjects: 148
Study 2991486 — intervention group
Group type: COMPARATOR
Intervention: BCNU (1,3‐bis(2‐chloroethyl)‐1‐nitrosourea)
Number of subjects: 148
Study 2991486 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 148
Study 2991486 — intervention group
Group type: COMPARATOR
Intervention: BCNU
Number of subjects: 148
Study 30740936 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser dissection mass spectrometry (LDMS)
Number of subjects: 640
Study 30740936 — intervention group
Group type: COMPARATOR
Intervention: Congo red (CR) staining followed by immunohistochemistry (IHC)
Number of subjects: 640
Study 30740936 — intervention group
Group type: EXPERIMENTAL
Intervention: LDMS
Number of subjects: 640
Study 29406451 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological workbook (LEARN technique and goal setting)
Number of subjects: 139
Study 29406451 — intervention group
Group type: COMPARATOR
Intervention: Information-only workbook (control)
Number of subjects: 139
Study 27352955 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence (≥80% medication adherence)
Number of subjects: 699
Study 27352955 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherence (<80% medication adherence)
Number of subjects: 699
Study 27352955 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 699
Study 24659797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg
Number of subjects: 464
Study 24659797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg
Number of subjects: 464
Study 24659797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Number of subjects: 464
Study 24659797 — intervention group
Group type: COMPARATOR
Intervention: Ponesimod
Number of subjects: 464
Study 24659797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 22976260 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium (1.5 g powdered flower, 3 days a week for 2 months)
Number of subjects: 31
Study 22976260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 20200346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 640
Study 20200346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study 18034664 — intervention group
Group type: EXPERIMENTAL
Intervention: Active knowledge transfer (knowledge brokers visiting every 2 months for 1 year, 2 hours per visit)
Number of subjects: 72
Study 18034664 — intervention group
Group type: COMPARATOR
Intervention: Passive knowledge transfer (evidence-based knowledge material available on Internet every week for 1 year)
Number of subjects: 72
Study 15618787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 15618787 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 90
Study 12394379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (10 colony-forming units daily)
Number of subjects: 220
Study 12394379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (comparable to GG)
Number of subjects: 220
Study 12394379 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 220
Study 12394379 — intervention group
Group type: COMPARATOR
Intervention: Non-breast-fed
Number of subjects: 220
Study 10480513 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic enrollees
Number of subjects: 0
Study 10480513 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic enrollees
Number of subjects: 0
Study 8628880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D stereotaxic surface projection (SSP)
Number of subjects: 39
Study 8628880 — intervention group
Group type: COMPARATOR
Intervention: Standard transaxial display
Number of subjects: 39
Study 1960663 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde-tyrothricin solution placed in periodontal pockets
Number of subjects: 14
Study 1960663 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution placed in periodontal pockets (Control)
Number of subjects: 14
Study 6452797 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg
Number of subjects: 10
Study 6452797 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg
Number of subjects: 10
Study 6452797 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 300 mg
Number of subjects: 10
Study 6452797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31851385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and dose-dense (DD) epirubicin and cyclophosphamide followed by docetaxel + 1 year of adjuvant trastuzumab
Number of subjects: 342
Study 31851385 — intervention group
Group type: COMPARATOR
Intervention: Standard 5-fluorouracil, epirubicin, and cyclophosphamide plus docetaxel every 3 weeks + 1 year of adjuvant trastuzumab
Number of subjects: 342
Study 29859132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 14
Study 29859132 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 14
Study 29146647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment (NOT) consisting of intravenous antibiotics for 48-72 hours, daily blood tests, and ultrasound follow-up, followed by oral antibiotics if discharge criteria are met.
Number of subjects: 334
Study 29146647 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 334
Study 29146647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment (NOT)
Number of subjects: 334